BeiGene Shares Rise on First Dosing of Brukinsa
By Dean Seal
American depositary receipts of BeiGene jumped after the company said the first doses of its lymphocytic leukemia treatment Brukinsa have been administered to patients in Armenia and Nepal.
The stock was up 9% at $179 in premarket trading. Shares had fallen 9% year-to-date when the market closed Tuesday.
The oncology company said Wednesday morning that the initial dosing comes as part of a three-year collaboration with a health equity nonprofit, The Max Foundation, and its own nonprofit charitable foundation to provide access to medicine in low- and middle-income countries.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 13, 2024 08:42 ET (12:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing